# Raludotatug deruxtecan

Source: https://onco.cc/drugs/raludotatug-deruxtecan/  
OnCo record `raludotatug-deruxtecan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Raludotatug deruxtecan is a CDH6 ADC in phase 3 for platinum-resistant ovarian cancer.

## Summary

Raludotatug deruxtecan is an anti-CDH6 IgG1 antibody linked through a cleavable GGFG linker to DXd, a topoisomerase I inhibitor that traps the enzyme on DNA and collapses replication forks; the payload crosses membranes, giving a bystander effect. CDH6 is a cadherin overexpressed in ovarian and renal cell carcinoma with little normal-tissue expression. Developed by Daiichi Sankyo with Merck, it produced an objective response rate around 46 percent in phase 1 in heavily pretreated ovarian cancer, and the REJOICE-Ovarian01 phase 2/3 trial is comparing it with chemotherapy in platinum-resistant disease at 5.6 mg/kg every 3 weeks. Nausea, fatigue, neutropenia and anaemia are the main toxicities, with interstitial lung disease monitored as for other DXd conjugates. Whether the response rate holds in a randomised trial is the open question for platinum-resistant ovarian cancer.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-04
- Code: R-DXd, DS-6000
- Modality: ADC
- Mechanism: Anti-CDH6 IgG1 with DXd.
- Payload: DXd
- Linker: GGFG cleavable
- Dosing: IV infusion; 5.6 mg/kg every 3 weeks (phase 2/3 dose)

## Sources

- ClinicalTrials.gov: trials of Raludotatug deruxtecan: https://clinicaltrials.gov/search?intr=R-DXd

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CDH6](https://onco.cc/targets/cdh6/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- terms: [DXd](https://onco.cc/terms/dxd/), [Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)](https://onco.cc/terms/ggfg/), [Topoisomerase-I inhibitor payloads](https://onco.cc/terms/topoisomerase-i-payloads/)
- trials: [A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)](https://onco.cc/trials/nct06843447/), [A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)](https://onco.cc/trials/nct06780085/), [A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)](https://onco.cc/trials/nct06864169/), [A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)](https://onco.cc/trials/nct06660654/), [REJOICE-Ovarian01](https://onco.cc/trials/rejoice-ovarian01/)

---
JSON: https://onco.cc/api/v1/entities/raludotatug-deruxtecan.json